Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury

Diabetologia

Volumn 40, Issue 6, 1997, Pages 619-628

  Soulis, T ^a   Thallas, V ^a   Youssef, S ^a   Gilbert, R E ^a   McWilliam, B G ^b   Murray McIntosh, R P ^b   Cooper, M E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aminoguanidine; Aorta; Glycation; Kidney; Retina

Indexed keywords

AMINOGUANIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLYCATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; RAT; TISSUE DISTRIBUTION;

ANIMALS; AORTA; BLOOD GLUCOSE; BODY WEIGHT; CATTLE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE SUSCEPTIBILITY; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; KIDNEY GLOMERULUS; LUNG; MALE; MESENTERIC ARTERIES; MICROCIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RETINA; SERUM ALBUMIN, BOVINE;

EID: 0030811664     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050725     Document Type: Article

References (53)

1. Brownlee M (1994) Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 43: 836-841
2. Fu MX, Knecht KJ, Thorpe SR, Baynes JW (1992) Role of oxygen in cross-linking and chemical modification of collagen by glucose. Diabetes 2: 42-48
3. Monnier V, Vishwanath V, Frank K, Elmets G, Dauchot P, Kohn R (1986) Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Eng J Med 314: 403-408
4. Monnier VM, Sell DR, Nagaraj RH, et al. (1992) Maillard reaction-mediated molecular damage to extracellular matrix and other proteins in diabetes, aging, and uremia. Diabetes 2: 36-41
5. Sensi M, Pricci F, Pugliese G, et al. (1995) Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res Clin Pract 28: 9-17
6. Nicholls K, Mandel T (1989) Advanced glycosylation end products in experimental murine diabetic nephropathy: effect of islet grafting and of aminoguanidine. Lab Invest 60: 486-489
7. Soulis Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
8. Hammes H, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558
9. Cameron NE, Cotter MA, Dines K, Love A (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35: 946-950
10. Neeper M, Schmidt A, Brett J et al. (1992) Cloning and expression of a cell surface receptor for advanced glycation end products of proteins. J Biol Chem 267: 14998-15004
11. Schmidt A, Vianna M, Gerlach M et al. (1992) Isolation and characterisation of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987-14997
12. Schmidt AM, Mora R, Cao R et al. (1994) The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882-9888
13. McWilliam B, Ruger B, Neale T, Murray-McIntosh R (1994) Detection of glucose-6-phosphate derived advanced glycosylation end products in diabetic nephrophathy. Kidney Int 46: 939 (Abstract)
14. Brownlee M, Vlassara H, Cerami A (1985) Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34: 938-941
15. Schmidt F (1961) Enzymatic determination of glucose and fructose simultaneously. Klin Woch 39: 1244-1247
16. Cooper M, Rumble J, Komers R, Du H, Jandeleit K, Chou S (1994) Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 43: 1221-1228
17. Shankland S, Scholey J, Ly H, Thai K (1994) Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 46: 430-442
18. Brett J, Schmidt AM, Yan SD et al. (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712
19. Sell DR, Monnier VM (1990) End-Stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85: 380-384
20. McCance DR, Dyer DG, Dunn JA et al. (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478
21. Soulis T, Cooper M, Vranes D, Bucala R, Jerums U (1996) The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50: 627-634
22. Nakayama H, Mitsuhashi T, Kuwajima S et al. (1993) Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 42: 345-350
23. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138
24. Kume S, Takeya M, Mori T et al. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 147: 654-667
25. Shikata K, Makino H, Sugimoto H et al. (1995) Localization of advanced glycation endproducts in the kidney of experimental diabetic rats. J Diabetes Complications 9: 269-271
26. Nakamura Y, Horii Y, Nishino T et al. (1993) Immunohistochemical localisation of advanced glycation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Path 143: 1649-1656
27. Bucala R, Vlassara H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26: 875-888
28. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy. Diabetologia 38: 387-394
29. Noshino T, Horii Y, Shiiki H (1995) Immunohistochemical detection of advanced glycation end products within the vascular lesions and glomeruli in diabetic nephropathy. Human Path 26: 308-313
30. Wautier JL, Wautier MP, Schmidt AM et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742-7746
31. Schmidt AM, Hori O, Chen JX et al. (1995) Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96: 1395-1403
32. Schmidt AM, Hasu M, Popov D et al. (1994) Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91: 8807-8811
33. Abel M, Ritthaler U, Zhang Yet al. (1995) Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 10: 1662-1667
34. Lin S, Huang Y (1996) Receptor for advanced glycation endproducts is upregulated within diabetic kidney tissue: potential role in diabetic nephropathy. JASN 7: 1874
35. Hori O, Brett J, Slattery T et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761
36. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K (1994) Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37: 32-35
37. Kihara J, Schmelzer J, Pudusio J, Curran G, Nickander K, Low P (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88: 6107-6111
38. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K (1992) Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabet Metab 41: 47-52
39. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
40. Ritthaler U, Deng Y, Zhang Y et al. (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146: 688-694
41. Palinsky W, Koschinsky T, Butler S (1995) Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 15: 571-582
42. Jerums G, Soulis T, Panagiotopoulos S, Cooper M (1995) In vivo effects of aminoguanidine in experimental diabetes and atherosclerosis. Diabetes Medical International Series 1100: 299-305
43. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14: 1521-1528
44. Gugliucci A, Bendayan M (1996) Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39: 149-160
45. Makita Z, Bucala R, Rayfield EJ et al. (1994) Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343: 1519-1522
46. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440
47. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker G, Striker L (1992) Receptor specific increases in extracellular matrix productions in mouse mesangial cells by AGEP is mediated via platelet growth factor. Proc Natl Acad Sci USA 89: 2843-2877
48. Throckmorton D, Brogden A, Min B, Rasmussen H, Kashgarian M (1995) PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycation end product. Kidney Int 48: 111-117
49. Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A (1988) Cachetin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240: 1546-1548
50. Kirstein M, Aston C, Hintz R, Vlassara H (1992) Receptor specific induction of IGF-1 in human monocytes by AGEP-modified proteins. J Clin Invest 90: 439-446
51. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H (1991) Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 174: 931-939
52. Vlassara H, Li YM, Imani F et al. (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1: 634-646
53. Wautier JL, Zoukourian C, Chappey O et al. (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97: 238-243